



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : A61K 38/27, C12N 5/06	A2	(11) International Publication Number: WO 00/30675 (43) International Publication Date: 2 June 2000 (02.06.00)
(21) International Application Number: PCT/SE99/02197 (22) International Filing Date: 25 November 1999 (25.11.99) (30) Priority Data: 9804064-5 25 November 1998 (25.11.98) SE (71) Applicant (for all designated States except US): A+ SCIENCE INVEST AB [SE/SE]; P.O. Box 3096, S-400 10 Göteborg (SE). (72) Inventor; and (75) Inventor/Applicant (for US only): ERIKSSON, Peter [SE/SE]; Dr. Saléns Gata 10, S-413 22 Göteborg (SE). (74) Agent: AWAPATENT AB; P.O. Box 11394, S-404 28 Göteborg (SE).		(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF CONDITIONS AFFECTING NEURAL STEM CELLS OR PROGENITOR CELLS (57) Abstract Use of a substance that upon administration will lead to increased concentrations of growth hormone, such as growth hormone, a functionally equivalent analogue thereof or a substance that will increase the release of endogenous growth hormone, for the production of a medicinal product for treatment of abnormal conditions affecting neural stem cells, progenitor cells and/or cells derived from neural stem cells or progenitor cells, especially conditions affecting the oligodendroglia, astroglia, and/or neuronal cells. In vitro and in vivo methods for inducing lineage determination, propagating and/or inducing or maintaining the genesis of neurons, oligodendrocytes, astroglial cells from progenitor cells, stem cells and/or cells derived from said cells by administering to the cells a substance that increases the concentration of growth hormone. Also a method of reducing the genesis of oligodendrocytes, neurons, astroglial cells from progenitor cells or stem cells, wherein a pharmaceutically effective amount of a substance that will lead to a decreased concentration of growth hormone or a functionally equivalent analogue thereof is administered to said patient.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF CONDITIONS
AFFECTING NEURAL STEM CELLS OR PROGENITOR CELLS

Field of invention

The present invention relates to use of substances that upon administration to a patient will lead to increased concentrations of growth hormone for the production of medicinal products.

The present invention also relates to a method for treatment of abnormal conditions affecting neural stem cells or progenitor cells.

Background of the invention

The result of traumatic, asphyxial, hypoxic, ischemic, toxic, infectious, degenerative or metabolic insults to the central nervous system (CNS) of man may involve a certain degree of damage in several different cell types. Damage to the brain by trauma, asphyxia, toxins, ischemia or infections are frequently causing neurological and cognitive deficits. Degenerative diseases may cause loss of specific populations of cells. For instance Parkinson's disease is associated by specific loss of dopaminergic neurons in the Substantia nigra, similarly, multiple sclerosis is associated with loss of myelin and oligodendrocytes. Other examples of degenerative disorders caused by selective loss of a specialized type of neurons is Alzheimer's disease associated with loss of cholinergic neurons. There are many other instances in which CNS injury or disease can cause damage to oligodendroglia, astroglia or neuronal cells.

Furthermore, axonal regeneration and sprouting after injury to axons in the CNS white matter tracts and injury to the spinal cord has been shown to be inhibited by surface molecules expressed by oligodendrocytes.

Progenitor cells have been grown and propagated with growth factors like epidermal growth factor (EGF), which is a substance belonging to a different class than GH.

In general, replacement of neurons following degeneration or damage is not a characteristic of the mammalian brain. Neuronal loss is thus considered permanent. Prolonged postnatal neurogenesis has been described in the granule cell layer of the hippocampal formation (Altman, J., and Das, G.D., J. Comp. Neurol. 124: 319-335 (1965); Altman, J. and Das, G.D. Nature 214: 1098-1101 (1967); Caviness, V. S. jr., J. Comp Neurol. 151: 113-120 (1973); Gueneau, G., Privat, A., Drouet, J., and Court, L., Dev. Neurosci. 5, 345-358 (1982); Eckenhoff, M.F., and Rakic, P., J. Neurosci. 8: 2729-2747 (1988)). Neurogenesis has recently been shown to persist well into adulthood in man (Eriksson, P.S., Perfilieva, E., Björk-Eriksson, T., Alborn, A., Nordborg, C., Peterson, D.A., Gage, F.H., Nature Med. in press). Neuronal progenitor cells reside in the subgranular zone (SGZ) of the dentate gyrus where they continuously proliferate, migrate into the granulae cell layer and differentiate into granule cells (Kuhn, H., Dickinson-Anson, H., and Gage, F.H., J. Neurosci. 16: 2027-2033 (1996); Cameron, H.A., Woolley, C.S., McEwen, B.S., and Gould, E., Neuroscience 56: 337-344 (1993); Seki, T. and Arai, Y., J. Neurosci. 13: 2351-2358 (1993)). These newborn neurons in the granule cell layer express markers of differentiated neurons and have morphological characteristics corresponding to differentiated granulae cells (Kaplan, M.S. and Bell, D.H., J. Neurosci. 4: 1429-1441 (1984); Cameron, H.A., Woolley, C.S., McEwen, B.S. and Gould, E. Neuroscience 56: 337-344 (1993); Cameron, H.A., Woolley, C.S., and Gould, E., Brain Res. 611: 342-346 (1993)). Furthermore, they establish axonal processes into the mossy fiber pathway and form synaptic connections with their targets in hippocampus CA3 (Seki, T. and Arai, Y., J. Neurosci. 13: 2351-2358 (1993); Stanfield, B.B. and Trice, J.E. Exp. Brain

Res. 72: 399-406 (1988)). The hippocampus is associated with spatial learning and memory (McNamara, R.K, and Skelton, R.W., Brain Res. Rev. 18: 33-49 (1993)). The proliferation of progenitor cells can be influenced by the administration of n-methyl-d-aspartate (NMDA) receptor antagonists or by the removal of the adrenal glands (Cameron, H.A. and Gould, E. Neuroscience 61: 203-209 (1994); Cameron, H.A., Tanapat, P., and Gould, E., Neuroscience 82: 349-354 (1998)). Plasticity is reduced with increasing age, and recent studies have demonstrated that proliferation of progenitor cells also is decreased but not completely abolished with age (Kuhn, H., Dickinson-Anson, H., and Gage, F.H., J. Neurosci. 16: 2027-2033 (1996)). Stem cells isolated from the adult rodent brain has recently been transplanted into the brain of adult animals where they differentiate into cells with neuronal characteristics (Suhonen, J.O., Peterson, D.A., Ray, J. And Gage, F.H., Nature 383:624-627 (1996)).

Furthermore, neurogenesis in the dentate gyrus in young mice has been shown to be facilitated by enriched environments. It was shown that exposure to enriched environments leads to an increased number of surviving newly formed granulae cell neurons and an increased total number of neurons in the dentate gyrus (Kempermann, G., Kuhn, H. G., and Gage, F. H., Nature 386: 493-495 (1997)).

Summary of the invention

It has now been found that by using growth hormone, or an analogue thereof, or another substance leading to increased concentrations of growth hormone or analogues thereof, it is possible to modulate the proliferation and/or differentiation of neural stem cells and progenitor cells from the adult CNS. The present invention thus provides new possibilities to treat injuries to or diseases of the central nervous system that predominantly affect oligodendroglia, astroglia or neuronal cells by

modification of proliferation cell genesis and/or differentiation of neuronal stem cells or progenitor cells in the central nervous system.

It has also been found that it is possible to control the propagation in vitro of stem cells, progenitor-cells and other cells, especially cells derived from the central nervous system, with the potential to generate neurons, astrocytes or oligodendrocytes. Such cells may e.g. be used for therapeutic purposes in patients.

Thus, the present invention relates to the use of a substance that upon administration to a patient will lead to an increased concentration of growth hormone or a functionally equivalent analogue thereof for the production of a medicinal product for treatment of an abnormal condition affecting neural stem cells and/or progenitor cells.

The invention also relates to a method for treatment of an abnormal condition affecting neural stem cells and/or progenitor cells, wherein a pharmaceutically active amount of a substance that will lead to an increased concentration of growth hormone or a functionally equivalent analogue thereof is administered to a patient.

Furthermore, the invention relates to a method of inducing lineage determination, propagating and/or inducing or maintaining the genesis of neurons, oligodendrocytes, astroglial cells from progenitor cells, stem cells and/or cells derived from said cells by administration of an effective amount of growth hormone or a functionally equivalent analogue thereof to stem cells, progenitor cells, neurons astroglial cells and/or oligodendrocytes in vitro.

Another aspect of the invention relates to abnormal conditions in the CNS due to too high concentrations of growth hormone in the CNS.

The invention thus also relates to the use of a substance that upon administration to a patient will lead to a decreased concentration of growth hormone or a func-

tionally equivalent analogue thereof for the production of a medicinal product for treatment of an abnormal condition affecting stem cells, progenitor cells and/or cells derived from stem cells or progenitor cells, as well as to a method of reducing the genesis of oligodendrocytes, neurons, astroglial cells from progenitor cells or stem cells in, or derived from, the central or peripheral nervous system in a patient, wherein a pharmaceutically effective amount of a substance that will lead to a decreased concentration of growth hormone or a functionally equivalent analogue thereof is administered to said patient.

The characterizing features of the invention will be evident from the following description and the appended claims.

Detailed description of the invention

The mammalian brain, including the human brain, retains its ability to generate neurons throughout life in certain brain regions. New neurons and astroglial cells and oligodendrocytes are generated by cell genesis from stem or progenitor cells. During the research leading to the present invention it was found that growth hormone (below denoted GH) induces an increase in cell genesis from progenitors/stem cells in the adult brain. It was also found that increased number of new cells in the hippocampus is associated with improvement in learning and memory. These findings lead to the insight that it is possible to manipulate neurological deficits, such as memory and learning deficits, in patients by manipulating the amount of GH present in the environment surrounding the cells.

It was thus found that it is possible to treat a CNS damage or deficit after an insult by increasing the number of stem cells or progenitor derived cells including neurons, astroglial cells and oligodendrocytes.

It was also found that it is possible to treat neural loss suffered after a CNS insult by increasing the number of stem cells or progenitor derived cells including neurons, astroglial cells and oligodendrocytes in a patient by increasing the concentration of GH in the patient to induce proliferation and/or differentiation of stem cells with a concomitant increase in cell genesis.

Finally it was found that it is possible to treat neural loss suffered after a CNS insult by increasing the number of stem cells or progenitor derived cells including neurons and/or astroglial cells and/or oligodendrocytes in a patient by increasing the concentration of GH in the patient to induce proliferation and/or differentiation of stem cells with a concomitant increase in cell genesis in order to facilitate the isolation through surgical removal of small samples of brain tissue containing said cells for further expansion in vitro and concomitant re-transplantation into the patient.

Thus, the present invention relates to the use of a substance that upon administration to a patient will lead to an increased concentration of growth hormone, or of an analogue thereof, for the production of a medicinal product for treatment of an abnormal condition affecting neural stem cells, progenitor cells and/or cells derived from neural stem cells or progenitor cells, as well as to a method for treatment of an abnormal condition affecting neural stem cells, progenitor cells and/or cells derived from neural stem cells or progenitor cells, wherein a pharmaceutically active amount of a substance that will lead to an increased concentration of growth hormone is administered to a patient.

The substance that will lead to an increased concentration of growth hormone or analogue thereof may e.g. be growth hormone itself, or a functionally equivalent analogue thereof. The term "functionally equivalent analogue thereof" relates to all substances that upon administration to a patient will have essentially the same biologi-

cal and pharmaceutical effect as GH. Such an analogue may e.g. be a synthetic GH mimetic. It is also possible to use a compound that upon administration to a patient will give rise to an elevated active concentration of GH or of a natural occurring GH analogue or its mediators in the CNS of the patient, e.g. by giving rise to an increased release of endogenous GH. For example, positively regulating binding proteins of GH may be used, such as the GH releasing substance growth hormone releasing peptide (GHRP) and analogous thereof.

The medicinal product according to the invention preferably comprises the active substance in a pharmacologically acceptable carrier or diluent such as those known in the art.

The medicinal product or the substance used according to the invention is preferably administered via intravenous peripheral infusion or via intramuscular or subcutaneous injection into the patient. It is also possible to administer the medicinal product or the pharmaceutically active substance through a surgically inserted shunt into a cerebral ventricle of the patient.

Preferably, the administered subcutaneous dosage range of the pharmaceutically active substance is about 0.01-1 IE/kg body weight of the patient per week.

The term "patient", as used herein, relates to any human or non-human mammal in need of treatment according to the invention.

The term "treatment" used herein relates to both treatment in order to cure or alleviate a disease or a condition, and to treatment in order to prevent the development of a disease or a condition. The term treatment also refer to the affecting of cell genesis from stem cells or progenitor cells, by inducing the genesis of neurons and/or glial cells after either neuronal, oligodendroglial or glial cell loss in the CNS or PNS (peripheral nervous system) or to prevent the normal age related deterioration in the CNS or PNS, the term also relates to

the cultivation of stem or progenitor cells for concomitant transplantation to the CNS or PNS in patients. The treatment may either be performed in an acute or in a chronic way.

5 As stated above the pharmaceutically active substance used according to the invention is suitable for treatment of abnormal conditions affecting neural stem cells, progenitor cells and/or cells derived from neural stem cells or progenitor cells. It can thus be used to
10 prevent, treat or ameliorate damages, diseases or deficits of central nervous system (CNS). The pharmaceutically active substance used according to the invention is especially suitable for treatment of conditions affecting the oligodendroglia, astroglia, and/or neuronal cells.
15 Such conditions may e.g. be a CNS damage or deficit, neuronal cell loss or memory loss. Such conditions may be caused by a number of different factors or diseases, such as multiple sclerosis, hypoxic injury, ischemic injury, traumatic injury, Parkinson's disease, and demyelination
20 disorder.

 The effect the pharmaceutically active substances used according to the invention is due to their ability to either induce cell genesis, proliferation and/or differentiation of progenitor derived cells in or from the
25 central nervous system.

 According to another embodiment of the invention it is possible to use growth hormone or a functionally equivalent analogue thereof in order to propagate progenitor cells or stem cells or other neural cells in a
30 tissue culture or a cell culture. Such cells may thereafter be used for cell transplantation into a patient suffering from neuronal cell loss or a condition due to lack of endogenous cells of this type. The cells used to start the culture may either originate from the patient itself
35 of from human or animal donors.

 When cells are to be removed from a patient for in vitro propagation it may be advantageous to first in-

crease the number of progenitor cells in the patient. This facilitating the subsequent isolation of said cells from patients facilitates the subsequent isolation of said cells from patients. The number of progenitor cells are increased by use of the method or medicinal product according to the invention, i.e. by the use of substance that upon administration to a patient will lead to an increased concentration of growth hormone or a functionally equivalent analogue thereof.

10 Growth hormone, or a functionally equivalent analogue thereof, may be used alone or in junction with other medicaments or growth factors such as epidermal growth factor (EGF) or fibroblast growth factor 2 (FGF2) designed to induce in cell genesis or proliferation in
15 the CNS or PNS. Growth hormone, or a functionally equivalent analogue thereof, alone or in conjunction with other medicaments, peptides, growthfactors, steroids, lipids, glycosylated proteins or peptides, either simultaneous or in sequence, may be used in order to facilitate cell
20 genesis or the generation of specific cell types in vivo or in vitro. It may also be used to induce immature, or multipotent cells to active specific developmental programs as well as specific genes in the aforementioned cells.

25 By the above mentioned cell genesis is meant the generation of new cells such as neurons oligodendrocytes schwancells and astroglial cells from multipotent cells, progenitor or stem cells within the adult CNS or PNS or in vitro.

30 Furthermore, the invention also relates to the therapeutic use of substances that decrease the amount of active GH or naturally occurring analogous of GH in the patient and thus decrease the genesis of oligodendrocytes in patients with axonal or spinal cord injury. Examples
35 of such substances are negatively regulating binding proteins, GH-receptor antagonists, drugs or antibodies or compounds or peptides. Axonal regeneration and spinal

cord injury have been shown to be inhibited by certain molecules expressed by oligodendrocytes. Furthermore, drugs or antibodies or compounds or peptides, that increase endogenous peptides, or proteins that decrease the biological activity of endogenous GH can also be used.

The invention will be more fully understood when reading the following example. It should not, however, be considered to limit the scope of the invention.

Brief description of the drawings

In the examples below, reference is made to the appended drawings on which:

- Fig. 1 shows the density of BrdU-positive cells after 7 days in the dentate gyrus of hypophysectomized (Hx) rats treated according to the invention with growth hormone (GH), together with cortisol (C), and L-thyroxine (T) compared to hypophysectomized rats treated with only C and T, and to a control group.
- Fig. 2 shows that animals treated with cortisone, thyroxine and GH, according to the invention, had significantly more granulae cell neurons than hypophysectomized animals treated with only cortisone and thyroxine four weeks after the last BrdU injection the hypophysectomized animals
- Fig. 3 shows that animals with increased number of new born cells according to the invention (○) performed significantly better in the hidden-platform version of the water maze task, used to assess spatial performance, than a control group (●).

Examples

In this example, the density of BrdU-positive cells in the dentate gyrus of hypophysectomized (Hx) rats treated according to the invention with growth hormone (GH), cortisol (C), and L-thyroxine (T) was compared to

the density of BrdU-positive cells in the dentate gyrus of hypophysectomized rats treated with cortisol (C), and L-thyroxine (T), and to the density of the same cells for an untreated unoperated control group.

5 Fisher rats (Harlan Sprague Dawley) which were intact or hypophysectomized at 50 days of age were maintained under standardized conditions of temperature (24-26°C), humidity (50-60%) and with lights on between 0500 and 1900 h.

10 The rats had free access to standard laboratory chow and water. Hormonal treatment started 7-10 days after hypophysectomy. All the hypophysectomized rats were given cortisol phosphate (400 µg/kg/day; Solu-Cortef, Upjohn, Puurs, Belgium) and L-thyroxine (10 µg/kg/day; Sigma, USA) diluted in saline as a daily subcutaneous injection (at 0800 h). Recombinant bovine GH (bGH) was diluted in 0.05 M phosphate buffer, pH 8.6, with 1.6% glycerol and 0.02% sodium azide. GH 1 mg/kg/day was given as one daily subcutaneous injection at 24 h intervals. The treatment
15 continued for seven days. Thereafter the rats were sacrificed and the brains taken out and prepared for immunohistochemistry.

Ten hypophysectomized rats were substituted with only cortisole and L-thyroxine. Fifteen hypophysectomized
25 rats were substituted with cortisole, L-thyroxine and GH. Ten rats weighing 120 g were assigned to a control group. During the seven days of the treatment period all animals received a daily intraperitoneal injection (50 mg/kg bodyweight) of bromodeoxyuridine (BrdU; Sigma). The thymidine analog BrdU is incorporated into the genetic material upon mitotic division whereafter it can be detected
30 immunohistochemically in the resulting cells. On the twentieth day all animals were sacrificed by a lethal dose of anesthetics and transcardially perfused with 4% paraformaldehyde. The brains were removed and postfixed
35 in 4% paraformaldehyde for 24h. and thereafter stored in 30% sucrose solution. Coronal freezing microtome sections

(40 μ m) were stored in cryoprotectant (25% ethylene glycol, 25% glycerin, 0.05 M phosphate buffer) at -20°C until processing for immunohistochemistry or immunofluorescence.

- 5 The number of BrdU positive cells in the dentate gyrus of the hippocampus were counted using unbiased counting techniques. For detection of BrdU-labeled nuclei in tissue sections, the following DNA denaturation steps preceded the incubation with mouse anti-BrdU antibody
- 10 1:400 (Boeringer Mannheim) : 2 h incubation in 50% formamide/2X SSC (0.3 M NaCl, 0.03 M sodium citrate) at 65°C, 5 min. Rinse in 2 x SSC, 30 min incubation in 2N HCl at 37°C, and 10 min. Rinse in 0.1M boric acid, pH 8.5. All stainings were performed on free floating 40 mm sections.
- 15 Free-floating sections were treated with 0.6% H₂O₂ in tris buffered saline (TBS) (0.15M NaCl, 0.1M Tris-HCl, pH 7.5) for 30 min to block endogenous peroxidase. Several rinses in TBS were then followed by incubation in TBS/0.25% Triton X-100/3% normal horse serum (TBS-TS) for 30 min and
- 20 incubation with primary antibody in TBS-TS overnight at 4°C. After rinsing in TBS-TS, the sections were incubated for 3 hr with biotinylated horse anti-mouse IgG, 1:160 secondary antibodies (Vector Laboratories, USA). After TBS rinsing avidin-biotin-peroxidase complex was applied
- 25 for 1 h followed by peroxidase detection for 5 minutes (0.25 mg/ml diaminobenzidine, 0.01% H₂O₂, 0.04% NiCl).

For the immunofluorescence, sections were treated for DNA denaturation as described above, followed by incubation in TBS-TS for 30 min. Thereafter the sections

30 were incubated with mouse-anti-Calbindin-D28k, 1:2000 (Sigma) for 16 h at 4°C and was detected with a Texas red conjugated donkey anti-mouse IgG. BrdU was detected with a FITC conjugated rabbit anti-BrdU antibody. Fluorescent signals were detected and processed using a confocal

35 scanning laser microscope (Bio-Rad MRC1024, Richmond, CA).

The total number of BrdU positive cells in the granule cell layer, the subgranular layer and the hilus and their corresponding sample volumes were determined in 7-9 coronal sections, 240 mm apart, that contained the dentate gyrus. Cell counting was done according to an optical dissector method to avoid over sampling errors.

The results are shown in figure 1. After 7 days, the number of newborn cells in the dentate gyrus is significantly increased in hypophysectomized animals substituted with GH, cortisone, and thyroxine compared to animals substituted with only cortisone and thyroxine. Furthermore, the rate of proliferation was significantly increased after administration of GH to hypophysectomized animals treated with cortisol and L-thyroxine as quantified after one week of substitution. These results clearly show that GH increase the proliferative rate of progenitor cells in the dentate gyrus in the hippocampus.

Furthermore, the rate of proliferation was significantly increased after administration of GH to hypophysectomized animals treated with cortisol and L-thyroxine as quantified after one week of substitution. This result suggest that GH affect the proliferative rate of progenitor cells in the dentate gyrus of the hippocampus.

Furthermore, the proliferation was increased in normal animals receiving treatment for one week with GH compared with normal controls and compared with the hypophysectomized animals that were substituted for one week and thereafter unsubstituted during the following 3 weeks. The number of BrdU positive cells were estimated one month after treatment with either cortisone and L-thyroxine or cortisone, L-thyroxine and GH. The results are shown in figure 2.

The results suggest that GH either direct or indirect promote proliferation or survival of cells resulting from neural cell progenitor proliferation in the dentate gyrus.

The inventors of the present invention are the first to show that growth hormone can regulate the proliferation and subsequent generation of neurons in the adult brain.

5 Rats with increased number of newborn cells were tested and compared with rats that had lower number of newborn cells four weeks after BrdU injection during four consecutive days. The rats were tested in a water maze with a video-tracking system. The time to reach the platform (latency) were monitored. The escape platform was
10 hidden 1 cm below the surface of the water at a fixed position. The water was made opaque by adding dry milk powder to the water. The water temperature was kept constant at 22°C throughout the test. Each animal was tested in
15 four trials each day. Each trial lasted 45 s. Animals that failed to find the hidden platform within 45 s were designated as having a 45-s latency and were put on the platform and allowed to stay there for 15 s.

 The latency in finding the platform during the water
20 maze test was analyzed with a two-way ANOVA, and repeated postcomparative tests at each monitored time interval were performed using the Scheffe *F*-test. The results are shown in figure 3. There were no significant difference in swim speed. It is evident that animals with increased
25 number of newborn cells in the dentate gyrus, due to treatment according to the invention, performed significantly better in the spatial learning task. These group of animals represent the data denoted with ○ in the figure. The data for the rats with the lower number of newborn
30 cells are denoted with ● in the figure.

CLAIMS

1. Use of a substance that upon administration to a patient will lead to an increased concentration of growth hormone or a functionally equivalent analogue thereof for the production of a medicinal product for treatment of an abnormal condition affecting neural stem cells, progenitor cells and/or cells derived from stem cells or progenitor cells.
2. Use according to claim 1, wherein said substance is growth hormone or a functionally equivalent analogue thereof.
3. Use according to claim 1, wherein said substance upon administration will increase the release of endogenous growth hormone.
4. Use according to any one of the claims 1-3, wherein said condition affects the oligodendroglia, astroglia, and/or neuronal cells.
5. Use according to any one of the claims 1-4, wherein said condition affects non-cholinergic neuronal cells, cholinergic neuronal cells, or glial cells.
6. Use according to any one of the claims 1-5, wherein said condition is a CNS damage or deficit.
7. Use according to any one of the claims 1-6, wherein said condition is neural cell loss.
8. Use according to any one of the claims 1-7, wherein said condition is memory loss.
9. Use according to any one of the claims 1-8, wherein said condition is caused multiple sclerosis, hypoxic injury, ischemic injury, traumatic injury, Parkinson's disease, and/or demyelinating disorder.
10. Use according to any one of the claims 1-9, wherein said medicinal product is formulated for intravenous infusion, intramuscular injection or subcutaneous injection.
11. Use according to any one of the claims 1-10, wherein said medicinal product is formulated so that the

active substance will pass into the ventricles of the patient's brain when it is administered to a patient.

12. Use according to any one of the claims 1-11, wherein said medicinal product is formulated so that the
5 active substance will pass into the cerebrospinal fluid of the patient when it is administered to a patient.

13. Use of a substance that upon administration to a patient will lead to a decreased concentration of growth hormone or a functionally equivalent analogue thereof for
10 the production of a medicinal product for treatment of an abnormal condition affecting the central nervous system.

14. Use according to claim 13, wherein said substance is a negatively regulating growth hormone binding protein, a functionally equivalent analogous thereof, an
15 antibody against growth hormone, a biologically active growth hormone receptor inhibitor, and/or an inhibitor of endogenous growth hormone release.

15. Use according to claim 13 or 14, wherein said abnormal condition is the consequence of axonal damage
20 caused by concussion, axonal damage caused by head trauma, axonal damage caused by small vessel disease in the CNS, damage to the spinal cord after disease and/or trauma.

16. A method of inducing lineage determination,
25 propagating and/or inducing or maintaining the genesis of neurons, oligodendrocytes, astroglial cells from progenitor cells, stem cells and/or cells derived from said cells by administration of an effective amount of growth hormone or a functionally equivalent analogue thereof to
30 stem cells, progenitor cells, neurons astroglial cells and/or oligodendrocytes in vitro.

17. A method of inducing lineage determination or inducing or maintaining the genesis of neurons, oligodendrocytes, astroglial cells from progenitor cells or stem
35 cells in, or derived from, the central or peripheral nervous system in a patient, wherein a pharmaceutically effective amount of a substance that will lead to an in-

creased concentration of growth hormone or a functionally equivalent analogue thereof is administered to said patient.

18. A method according to claim 17, wherein said
5 substance is growth hormone or a functionally equivalent analogue thereof.

19. A method according to claim 17, wherein said substance is a substance that increases the release of endogenous growth hormone.

10 20. A method according to claim 17, for treatment of an abnormal condition affecting the nervous system of a patient.

21. A method according to claim 20, wherein said condition affects the oligodendroglia, astroglia, and/or
15 neuronal cells.

22. A method according to claim 22, wherein said condition affects the non-cholinergic neuronal cells, cholinergic neuronal cells, or glial cells.

23. A method according to claim 20, wherein said
20 condition is a CNS damage or deficit.

24. A method according to claim 23, wherein said condition is neural cell loss.

25. A method according to claim 23, wherein said condition is memory loss.

25 26. A method according to claim 23, wherein said condition is caused by at least one factor selected from the group consisting of multiple sclerosis, hypoxic injury, ischemic injury, traumatic injury, Parkinson's disease, and demyelinating disorder.

30 27. A method according to claim 17, wherein said substance is administered by intravenous infusion, intramuscular injection or subcutaneous injection.

28. A method according to claim 17, wherein brain cells are removed from the patient after said administration, said brain cells then being propagated in vitro,
35 followed by transplantation of the obtained cells back into the brains of the patient.

29. A method according to claim 28, wherein an effective amount of growth hormone or a functionally equivalent analogue thereof is administered to said brain cells during in vitro propagation.

5 30. A method of reducing the genesis of oligodendrocytes, neurons, astroglial cells from progenitor cells or stem cells in, or derived from, the central or peripheral nervous system in a patient, wherein a pharmaceutically effective amount of a substance that will lead to a decreased concentration of growth hormone or a functionally
10 equivalent analogue thereof is administered to said patient.

31. A method according to claim 30, wherein said substance is administration to the peripheral or central
15 nervous system of said patient.

32. A method according to claim 30, wherein said substance is selected from the group consisting of negatively regulating growth hormone binding proteins, functionally equivalent analogous thereof, antibodies against
20 growth hormone, biologically active growth hormone receptor inhibitors, and inhibitors of endogenous GH release.

33. A method according to claim 30, for treatment of a central nervous system injury.

34. A method according to claim 33, wherein said injury
25 is the consequences of a factor selected from the group consisting of axonal damage caused by concussion, axonal damage caused by head trauma, axonal damage caused by small vessel disease in the CNS, damage to the spinal cord after disease or trauma.




Fig. 1




Fig. 2

2/2




Fig. 3

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 38/27, C12N 5/06	A3	(11) International Publication Number: WO 00/30675 (43) International Publication Date: 2 June 2000 (02.06.00)
(21) International Application Number: PCT/SE99/02197 (22) International Filing Date: 25 November 1999 (25.11.99) (30) Priority Data: 9804064-5 25 November 1998 (25.11.98) SE (71) Applicant (for all designated States except US): A+ SCIENCE INVEST AB [SE/SE]; P.O. Box 3096, S-400 10 Göteborg (SE). (72) Inventor; and (75) Inventor/Applicant (for US only): ERIKSSON, Peter [SE/SE]; Dr. Saléns Gata 10, S-413 22 Göteborg (SE). (74) Agent: AWAPATENT AB; P.O. Box 11394, S-404 28 Göteborg (SE).		(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 17 August 2000 (17.08.00)
(54) Title: MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF CONDITIONS AFFECTING NEURAL STEM CELLS OR PROGENITOR CELLS		
(57) Abstract <p>Use of a substance that upon administration will lead to increased concentrations of growth hormone, such as growth hormone, a functionally equivalent analogue thereof or a substance that will increase the release of endogenous growth hormone, for the production of a medicinal product for treatment of abnormal conditions affecting neural stem cells, progenitor cells and/or cells derived from neural stem cells or progenitor cells, especially conditions affecting the oligodendroglia, astroglia, and/or neuronal cells. In vitro and in vivo methods for inducing lineage determination, propagating and/or inducing or maintaining the genesis of neurons, oligodendrocytes, astroglial cells from progenitor cells, stem cells and/or cells derived from said cells by administering to the cells a substance that increases the concentration of growth hormone. Also a method of reducing the genesis of oligodendrocytes, neurons, astroglial cells from progenitor cells or stem cells, wherein a pharmaceutically effective amount of a substance that will lead to a decreased concentration of growth hormone or a functionally equivalent analogue thereof is administered to said patient.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/02197

A. CLASSIFICATION OF SUBJECT MATTER		
IPC7: A61K 38/27, C12N 5/06 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC7: A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0324037 A1 (AROONSAKUL, CHAOVANE), 19 July 1989 (19.07.89), claim 7	1-12,17-27
A	--	16,28-29
X	WO 9422469 A1 (OHIO UNIVERSITY), 13 October 1994 (13.10.94), claim 1 and the abstract	1-12,17-27
A	--	16,28-29
X	WO 9410292 A1 (NEUROSPHERES LTD.), 11 May 1994 (11.05.94), page 14, lines 25-26	16,28-29
A	--	1-12,17-27
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
8 May 2000		18-05-2000
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Carolina Palmcrantz/EÖ Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 99/02197

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 8805052 A1 (THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND), 14 July 1988 (14.07.88), page 3, line 19 - line 20; page 6, line 17 --	13-14
X	GB 2198134 A (SANDOZ LTD.), 8 June 1988 (08.06.88), page 24, line 1 - line 3; page 26, line 1 - line 3; page 26, line 14 - line 17 --	13-14
X	WO 9012811 A1 (THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND), 1 November 1990 (01.11.90), page 15, line 16, claims 1,10 --	13-14
A	WO 9615226 A1 (NEUROSPHERES HOLDINGS LTD.), 23 May 1996 (23.05.96), page 7, line 17 - page 8, line 2; page 8, line 15 - line 19 --	13-15,30-34
A	WO 9204442 A1 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA), 19 March 1992 (19.03.92) --	13-15,30-34
A	Dialog Information Services, File 155, Medline, Dialog accession no. 05805167, Medline accession no. 89262444, Morisawa K et al: "Factors contributing to cerebral hypomyelination in the growth hormone-deficient little mouse", Neurochem Res (UNITED STATES) Feb 1989, 14 (2) p 173-7 --	13-15,30-34
A	Progress in Neurobiology, Volume 56, 1998, Christine C. Stichel et al, "Experimental strategies to promote axonal regeneration after traumatic central nervous system injury" page 119 - page 148 -- -----	13-15,30-34

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 99/02197

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **17-34**
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 17-34 relate to methods of treatment of the human or animal body by therapy (Rule 39.1.(iv)). Nevertheless, a search has been executed and based on the alleged effects of the compounds.
2. ☒ Claims Nos.: **1, 13, 17 and 30**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
see next sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a):

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see next sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 99/02197

Box I.2

The wording "...a substance... will lead to an increased/decreased concentration of growth hormone or a functionally equivalent analogue thereof..." is a functional determination that is considered to cover many different substances in addition to those mentioned in the application. Therefore, the international search has been incomplete.

Box II

As is stated in Annex B to Administrative instructions under the PCT, in force July 1, 1992 (PCT GAZETTE 1992, June 25, pages 7062-9, see page 7063 and example 5) unity of invention exists only when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding "special technical features" - i.e. features that define a contribution which each of the inventions makes over the prior art. (c.f. PCT Rule 13.2)

A search for this "special technical feature" mentioned in PCT Rule 13.2 among the independent claims did not reveal such a unifying, novel technical feature. Accordingly, the following inventions were found:

Invention A, claims 1-12 and 16-29, concerns the use of a substance that upon administration to a patient will lead to an increased concentration of growth hormone for the production of a medicinal product for treatment of an abnormal condition affecting neural stem cells, progenitor cells and/or cells derived from stem cells or progenitor cells.

Invention B, claims 13-15 and 30-34, concerns the use of a substance that upon administration to a patient will lead to a decreased concentration of growth hormone for the production of a medicinal product for treatment of an abnormal condition affecting the central nervous system, e.g. an abnormal condition caused by axonal damage.

INTERNATIONAL SEARCH REPORT

Information on patent family members

02/12/99

International application No.

PCT/SE 99/02197

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0324037 A1	19/07/89	SE 0324037 T3 AT 157546 T DE 3856017 D,T ES 2109914 T GR 3025576 T US 4727041 A US 4897389 A US 4898856 A US 4898857 A	15/09/97 23/04/98 01/02/98 31/03/98 23/02/88 30/01/90 06/02/90 06/02/90
WO 9422469 A1	13/10/94	AU 6449594 A	24/10/94
WO 9410292 A1	11/05/94	AU 703729 B AU 4924197 A AU 5367694 A EP 0669973 A FI 952022 A JP 8502652 T NO 951617 A US 5750376 A US 5851832 A US 5980885 A WO 9416718 A	01/04/99 12/03/98 24/05/94 06/09/95 27/04/95 26/03/96 27/04/95 12/05/98 22/12/98 09/11/99 04/08/94
WO 8805052 A1	14/07/88	AT 120204 T CA 1333647 A DE 3853384 D,T EP 0301087 A,B SE 0301087 T3 JP 1501798 T US 4871717 A	15/04/95 20/12/94 31/08/95 01/02/89 22/06/89 03/10/89

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

02/12/99

PCT/SE 99/02197

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2198134 A	08/06/88	AT 285187 A	15/03/91
		AT 393384 B	10/10/91
		AU 614726 B	12/09/91
		AU 8040487 A	05/05/88
		BE 1002421 A	05/02/91
		CA 1310331 A	17/11/92
		CH 677794 A	28/06/91
		CY 1703 A	14/01/94
		DE 3736016 A,C	05/05/88
		DK 565987 A	01/05/88
		ES 2012521 A	01/04/90
		FI 87222 B,C	31/08/92
		FI 874761 A	01/05/88
		FR 2606018 A	06/05/88
		GR 871659 A	03/03/88
		HK 110393 A	29/10/93
		IE 59310 B	09/02/94
		IL 84302 A	10/06/93
		IT 1212033 B	08/11/89
		IT 8748544 D	00/00/00
		JP 1917056 C	23/03/95
		JP 3101685 A	26/04/91
		JP 6041475 B	01/06/94
		JP 63122693 A	26/05/88
		KR 9504960 B	16/05/95
		LU 87031 A	03/05/88
		NL 8702485 A	16/05/88
		NZ 222333 A	26/09/90
		PT 86018 A,B	01/11/87
		SE 466311 B,C	27/01/92
		SE 8704204 A	01/05/88
		US 5162311 A	10/11/92
		US 5321016 A	14/06/94

INTERNATIONAL SEARCH REPORT

Information on patent family members

02/12/99

International application No.

PCT/SE 99/02197

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9012811 A1	01/11/90	AT 118222 T CA 2053250 A CZ 284341 B CZ 9002112 A DD 293832 A DE 69016691 D,T DK 395417 T EP 0395417 A,B SE 0395417 T3 ES 2069684 T IE 66113 B JP 2882679 B JP 4504723 T SK 211290 A SK 279231 B US 5633263 A	15/02/95 27/10/90 14/10/98 15/03/95 12/09/91 05/10/95 12/06/95 31/10/90 16/05/95 13/12/95 12/04/99 20/08/92 05/08/98 05/08/98 27/05/97
WO 9615226 A1	23/05/96	AU 3836795 A CN 1170435 A EP 0792350 A FI 971956 A JP 10509592 T NO 972171 A US 5750376 A US 5851832 A US 5980885 A	06/06/96 14/01/98 03/09/97 04/07/97 22/09/98 07/07/97 12/05/98 22/12/98 09/11/99
WO 9204442 A1	19/03/92	AU 8864691 A	30/03/92